Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion type Assertion NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_head.
- NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion description "[Furthermore, in a cohort of patients with newly diagnosed RA, elevated PAR(2) expression in both CD14+ and CD3+ cells was significantly reduced 3 months after methotrexate or sulfasalazine treatment and this reduction correlated significantly with the reduction in the 28-joint Disease Activity Scale score (p<0.05).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_provenance.
- NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion evidence source_evidence_literature NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_provenance.
- NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion SIO_000772 22294633 NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_provenance.
- NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion wasDerivedFrom befree-2016 NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_provenance.
- NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_assertion wasGeneratedBy ECO_0000203 NP957623.RAssu0bCgvwJ3PPEezFQRlU6USbQwuIZUhoNG98ojJPK4130_provenance.